Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.
연구 개요
This study is a randomized, open-label, active controlled, parallel group study comparing the efficacy and safety of once weekly Somatrogon to daily Growth Hormone (Genotropin) in pre-pubertal children with short stature either born Small for Gestational Age (SGA) or with Idiopathic Short Stature (ISS). The planned study duration is 12 months with a screening period of up to 30 days. The study will consist of two groups: 140 children with SGA who are naïve to GH treatment will be randomized 1:1 to receive either Somatrogon or Genotropin for 12 months. A second group will include 114 children with ISS who are naïve to GH treatment who will be randomized 1:1 to receive either Somatrogon or Genotropin for 12 months.
- 스폰서
- 협력: 화이자
- 적응증
- ISS, SGA
- 중재
- Somatrogon, Genotropin
- 목표 등록
- 254명
- 시작일
- 2026-02-01
- 완료(예정)
- 2028-01-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.